Application of atomic force microscopy in cancer research

Deng, Xiaolei; Xiong, Fang; Li, Xiayu; Xiang, Bo; Zheng, Lingjie; Wu, Xu; Guo, Can; Li, Xiaoling; Li, Yong; Li, Guiyuan; Xiong, Wei; Zeng, Zhaoyang

doi:10.1186/s12951-018-0428-0

Cited by 155 publications

(133 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have suggested that patients with the BRAF V600E mutation should be overtreated to some extent [47], because BRAF mutations are an independent risk factor for lymph node metastasis and are closely related to tumor size and invasiveness [48][49][50][51][52][53][54][55][56][57]. Both the clinical studies and the basic medical studies performed here suggest that the presence of the BRAF mutation may lead to a decrease in the efficacy of iodine-131 treatment.…”

Section: Discussionmentioning

confidence: 72%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

Objective: To investigate the correlation between the BRAF V600E gene mutation and clinicopathological features and thyroid function after iodine-131 treatment in patients with papillary thyroid cancer (PTC). Methods: A total of 128 PTC patients who underwent iodine-131 treatment after a total thyroidectomy from February 2015 to November 2016 at Hunan Cancer Hospital, China, were recruited. There were 25 males and 103 females. The age range was 11 to 73 years old. The BRAF V600E mutation in tumor tissues was detected by amplification-restriction mutation system polymerase chain reaction (ARMS-PCR), and the serum levels of Tg, TSH, Tg-Ab, and Tpo-Ab were measured by chemiluminescence after iodine-131 treatment. The BRAF V600E mutation was shown to be associated with clinicopathological characteristics and thyroid function indicators after iodine-131 treatment. Results: BRAF V600E mutation was detected in 75 of the 128 patients (58.6%) and was observed more frequently in cases with elevated Tg levels (Tg>1.00) at 3, 6, 12, and 18 months after treatment compared with patients without any BRAF mutations (P<0.05). Patients with BRAF V600E mutation had significant lower level of Tg-Ab at 3 and 12 months after treatment with iodine-131 than patients without BRAF V600E mutation (P<0.05). Among the 75 BRAF V600E patients, no significant association was found between the levels of TSH and Tpo-Ab after iodine-131 treatment (P>0.05). The BRAF V600E mutation was closely associated with the high-risk and age of the patient (≥45 years old) (P<0.05), but there was no significant correlation with gender, clinical stage, and distant metastasis. Conclusion:The BRAF V600E mutation is closely related to serum Tg elevation after treatment with iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a predictor of the efficacy of iodine-131 treatment for papillary thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 72%

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

Wang

et al. 2020

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, the malignant progression and high mortality rates associated with these tumors are related to their insidious onset, frequent metastasis and recurrence, and poor prognosis . Treatment on the basis of early diagnosis is still the main approach for achieving long‐term cancer‐free survival . Although many biomarkers of malignant tumors are currently used in the clinical setting, all of these biomarkers have limitations.…”

Section: Discussionmentioning

confidence: 99%

“…[29][30][31] Treatment on the basis of early diagnosis is still the main approach for achieving long-term cancer-free survival. [32][33][34][35][36] Although many biomarkers of malignant tumors are currently used in the clinical setting, all of these biomarkers have limitations. Therefore, many studies have focused on identifying more effective biomarkers to improve the early diagnosis of ma- 55 Moreover, hsa_circ_0033155 could serve as a biomarker or therapeutic target in non-small-cell lung cancer.…”

Section: Discussionmentioning

confidence: 99%

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Novel diagnostic and prognostic biomarkers of cancers are needed to improve precision medicine. Circular RNAs act as important regulators in cancers at the transcriptional and posttranscriptional levels. The circular RNA circMAN1A2 is highly expressed in nasopharyngeal carcinoma according to our previous RNA sequencing data; however, the expression and functions of circMAN1A2 in cancers are still obscure. Therefore, in this study, we evaluated the expression of circMAN1A2 in the sera of patients with nasopharyngeal carcinoma and other malignant tumors and analyzed its correlations with clinical features and diagnostic values. The expression levels of circMAN1A2 were detected by quantitative real‐time PCR, and the correlations of clinical features with circMAN1A2 expression were analyzed by χ2 tests. Receiver operating characteristic curves were used to evaluate the clinical applications of circMAN1A2. The results showed that circMAN1A2 was upregulated in nasopharyngeal carcinoma, oral cancer, thyroid cancer, ovarian cancer, and lung cancer, with areas under the curves of 0.911, 0.779, 0.734, 0.694, and 0.645, respectively, indicating the good diagnostic value of circMAN1A2. Overall, our findings suggested that circMAN1A2 could be a serum biomarker for malignant tumors, providing important insights into diagnostic approaches for malignant tumors. Further studies are needed to elucidate the mechanisms of circMAN1A2 in the pathogenesis of cancer.

show abstract

“…Liquid biopsy is currently an effective and non-invasive method. Some serum markers, such as Epstein Barr virus DNA and microRNA (miRNA), lactate dehydrogenase, and antigens have been recognized fortheir clinical value [4][5][6][7][8][9][10][11]. However, they also have some limitations.…”

Section: Introductionmentioning

confidence: 99%

Upregulation of long non-coding RNA LOC284454 may serve as a new serum biomarker for head and neck cancers

Fan¹,

Wang²,

Tang³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: Identification of effective diagnostic and prognostic biomarkers of cancer is necessary for improving precision medicine. Long non-coding RNAs(lncRNAs) play an important regulatory role in tumorinitiation and progression. The lncRNA LOC284454 is distinctly expressed in various head and neck cancers(HNCs), as demonstrated by our previous bioinformatics analysis. However, the expression levels and functions of LOC284454 in cancer are still unclear.Methods: We investigated the dysregulation of lncRNAs in HNCs using the GEO database and found that LOC284454 was highly expressed in HNCs. Serum samples from 212 patients with HNCs and 121 normal controls were included in this biomarker study. We measured the expression of LOC284454 in the sera of HNC patients and normal controls using RT-qPCR. Receiver operating characteristics (ROC) analysis is an important statistical method that is widely used in clinical diagnosis and population screening. ROC was used to analyze the clinical value of LOC284454 in the early diagnosis of HNCs.Results: LOC284454 was significantly upregulated in the sera of patients with nasopharyngeal carcinoma, oral cancer, and thyroid cancer. LOC284454 upregulation had good clinical diagnostic value in these cancers, as evaluated by area under the ROC curve values of 0.931, 0.698, and 0.834,respectively.Conclusions: LOC284454 may be a valuable serum biomarker forHNCsfacilitating the early diagnosis of malignant cancers.Further studies are needed to elucidate the mechanisms underlying the involvement of LOC284454 in HNCs.This study provides the first evidence that LOC284454 may be a serum biomarker for HNCs.

show abstract

Application of atomic force microscopy in cancer research

Cited by 155 publications

References 172 publications

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer

circMAN1A2 could serve as a novel serum biomarker for malignant tumors

Upregulation of long non-coding RNA LOC284454 may serve as a new serum biomarker for head and neck cancers

Contact Info

Product

Resources

About